Contemporary OB/GYN

07/26/2026

In our Sunday Spotlight article of the Week, Lisa A. Bukovac, DO, FACOG, of Ob Hospitalist Group (https://hubs.li/Q04qJWcD0), explains how placental biomarker testing can identify which patients with suspected require hospitalization and which can be safely monitored.

WATCH:

07/25/2026

In our Article of the Week, we highlight a recent study of associations between -1s and broad menstrual adverse event signals that found:

- Semaglutide generated the broadest menstrual adverse event signal profile in a FAERS analysis of reproductive-aged patients, including heavy bleeding, menstrual clots, and anovulatory cycles.

- Tirzepatide produced signals for intermenstrual bleeding and menstrual clots, while liraglutide generated no significant menstrual signals.

Read more: https://hubs.li/Q04qJFzn0

07/24/2026

Updated:

On July 16, CMS published the proposed rule via Federal Register, The Daily Journal of The United States Government, with specific proposal language for the proposed 15 new HCPCS G-codes for CY 2027 related to obstetrics billing.

In part, CMS stated the proposed G-codes would "reflect the previous MMM global code structure… These HCPCS G-codes would adopt all current conditions of payment for the MMM global codes, as well as maintain the MMM global period, if finalized.”

View the proposed codes here:

ACOG warns that CMS’ proposed G-codes for 2027 would create a dual maternity billing system, worsening disparities while increasing confusion.

07/24/2026

If you missed it, Calbeth C. Alaribe DMSc, MPH, PA-C, CPCHE, joined us at for a crucial discussion that highlighted a lack of evidence and research among Black women with endometriosis and potential associations with preeclampsia and eclampsia.

In this clip, Alaribe describes the risk of in a patient diagnosed with endometriosis.

Watch our full interview with Alaribe here: https://hubs.li/Q04qn72b0

07/22/2026

This year at , we spoke with Calbeth C. DMSc, MPH, PA-C, CPCHE, DMSc, MPH, PA-C, CPCHE, about her abstract highlighting a lack of research in Black women with . Specifically, a scoping review found no studies examining the association between preeclampsia, eclampsia, and endometriosis among Black women.

Watch the full discussion and learn more about Alaribe's call to action regarding new research in this underrepresented area, here: https://hubs.li/Q04qkPkl0

07/21/2026

Thank you, Connor Frey, MD, of The University of British Columbia, Vancouver Program, for speaking with Contemporary OB/GYN about the study "Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients," published in O & G, from the American College of Obstetricians and Gynecologists (ACOG).

Find the full interview and learn more about 's association to broad menstrual adverse event signals in reproductive-aged patients: https://hubs.li/Q04qbtqx0

07/20/2026

Could opt-out testing reduce stigma?

Damian P. (PAT) Alagia III, MD, MS, MBA, of Quest Diagnostics, argues that making STI testing universal removes the burden on patients to request it — and addresses clinician discomfort discussing sexual health.

"We're just going to take care of you, and part of taking care of you includes general testing," he says.

Watch more of the discussion here: https://hubs.li/Q04q248Y0

07/20/2026

A FAERS pharmacovigilance analysis published in Obstetrics & Gynecology found semaglutide generated signals for heavy menstrual bleeding, menstrual clots, intermenstrual bleeding, oligomenorrhea, and anovulatory cycles in female patients aged 12 to 55 years.

Full details:
https://hubs.li/Q04q08Yy0